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PERSPECTIVE
DNp73b puts the brakes on DNA repair
Emma Vernersson-Lindahl and Alea A. Mills1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
Mammalian cells are barraged with endogenous meta-
bolic byproducts and environmental insults that can lead
to nearly a million genomic lesions per cell per day.
Networks of proteins that repair these lesions are es-
sential for genome maintenance, and a compromise in
these pathways propagates mutations that can cause
aging and cancer. The p53 tumor suppressor plays a cen-
tral role in repairing the effects of DNA damage, and has
therefore earned the title of ‘‘guardian of the genome.’’ In
this issue of Genes & Development, Wilhelm and col-
leagues (pp. 549–560) demonstrate that p73—an older
sibling of p53—inhibits pathways that resolve DNA
double-strand breaks.
p53 and its relatives
Consisting of only three members, p53 and p53-like (p63
and p73) transcription factors make up a small but
influential family. p53-related proteins share three highly
conserved motifs: an N-terminal transactivation (TA)
domain, a core DNA-binding domain, and a C-terminal
oligomerization domain (Lunghi et al. 2009). p63 and
p73—the more ancient members of the family—contain
a sterile a motif that is not present in the more recently
evolved member, p53. The p53, p63, and p73 genes each
express multiple isoforms due to usage of alternative
promoters at the N terminus and various splicing events
at the C terminus. The p73 gene, for example, contains
dual promoters, and use of the transcriptional start site
located upstream of exon 1 produces TAp73 isoforms
containing a p53-like TA domain, whereas use of an
internal transcriptional start site downstream from exon
3 gives rise to the truncated DNp73 isoforms lacking this
p53-like TA domain. Furthermore, a complex series of
splicing events at the C terminus subdivides both the
TAp73 and DNp73 classes into a, b, g, d, e, u, z, and h
isoforms (Lunghi et al. 2009).
Despite their structural homology—which is most pro-
nounced within the central DNA-binding domain—p53
family members have distinct biological functions. p53
plays an undisputed role as a tumor suppressor, as it is
frequently lost or inactivated in human cancer. Further-
more, p53-deficient mice are highly susceptible to spon-
taneous tumors (Donehower et al. 1992). In contrast, the
role of p63 and p73 in cancer has been more elusive. Lack
of p63 is lethal, and mice are born without limbs or
stratified epithelia and its associated structures (Mills
et al. 1999; Yang et al. 1999). Although this severe
developmental phenotype led to the discovery that p63
mutations cause seven different developmental syn-
dromes in humans (Rinne et al. 2007), it has hampered
a direct analysis of tumor predisposition in mice com-
pletely lacking p63. Nonetheless, it is clear that p63
heterozygous mutant mice do not have a tumor-prone
phenotype comparable with that characteristic of p53
heterozygous mutant mice (Flores et al. 2005; Perez-
Losada et al. 2005; Keyes et al. 2006). p73 also functions
during embryogenesis, as p73 homozygous mutant mice
have neurological and inflammatory abnormalities, and
frequently succumb to an early death. Although it was
reported initially that p73-deficient mice were not pre-
disposed to spontaneous tumors (Yang et al. 2000), a later
report indicated that these mice were slightly tumor-
prone, and that mice heterozygous for both p63- and p73-
null alleles develop tumors with decreased latency, with
the wild-type alleles frequently being lost (Flores et al.
2005). While these studies lend some support for a tumor-
suppressive role for these more recently discovered mem-
bers of the p53 family, they were designed to completely
disrupt p63 and p73, and therefore are not able to address
the roleof individual isoforms.With the recentavailability
of isoform-specific DN and TA mouse models—as de-
veloped byWilhelm et al. (2010) for DNp73—the function
of individual family members has been further defined.
The DNA damage response (DDR)
p53’s tumor-suppressive function is attributed in large
part to its role in the DDR (Fig. 1). Under normal cellular
conditions, p53 levels are kept in check by MDM2-
mediated degradation (Momand et al. 1992; Jones et al.
1995; Montes de Oca Luna et al. 1995). In response to
dsDNA breaks induced by DNA-damaging agents such as
anti-cancer therapeutic compounds and ionizing radia-
tion, the MRN (MRE11–RAD50–NBS1) complex local-
izes to damaged sites and mediates activation of the
protein kinase ataxia telangiectasia mutated (ATM). Ac-
tivated ATM phosphorylates MDM2, thereby targeting it
[Keywords: p73; p53; neurodegeneration; DNA damage response; apo-
ptosis]
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for degradation and releasing its constraints on p53. ATM
also directlymodulates p53 via phosphorylation of Ser 15,
priming p53 for further modifications and activation
(Meek 2009). Efficient activation of ATM requires the
DNA damage checkpoint protein 53BP1. When 53BP1 is
depleted, ATM can no longer undergo efficient autophos-
phorylationandactivation (WilsonandStern2008). Indeed,
deficiency of 53BP1 sensitizes cells to ionizing radiation
and enhances tumorigenesis in vivo (Ward et al. 2003).
In the study in this issue of Genes & Development,
Wilhelm et al. (2010) generated mice that are specifically
lacking the DNp73 class of p73 proteins. They demon-
strate a neuroprotective role for DNp73, in agreement
with previous reports (Pozniak et al. 2000; Tissir et al.
2009). Furthermore, Wilhelm et al. (2010) discovered that
DNp73b inhibits p53 activation via a direct interaction
with 53BP1, thus incorporating DNp73b in the growing
network of proteins regulating the p53-dependent DDR.
A role for p73 in the DDR has long been recognized.
Flores et al. (2002) demonstrated that, in response to
DNA damage, mouse embryonic fibroblasts (MEFs) de-
ficient for p73 are partially resistant to apoptosis, and that
the combined lack of both p63 and p73 impairs p53-
dependent apoptosis in cultured cells and in vivo. Con-
versely, Senoo et al. (2004) found that, in the context of T
cells in vivo, p53-mediated apoptosis was unaffected by
depletion of p63 and/or p73. These findings suggest that
the role of p73 and p63 in modulating p53-mediated apo-
ptosis might not be a generalized feature, but rather is
highly influenced by the cellular context. The above work,
although elegant, does not address the extent to which
individual p73 isoforms affect p53-mediated responses.
Having engineered a mouse model lacking DNp73
isoforms, and observing neuronal phenotypes suggestive
of cellular depletion, Wilhelm et al. (2010) found that
DNp73/ MEFs were indistinguishable from wild-type
controls. However, treatment with DNA-damaging agents
that induce double-strand breaks revealed that cells lack-
ing DNp73 had enhanced sensitivity; this result was
recapitulated in g-irradiated DNp73/ thymocytes, and
further via siRNA knockdown of DNp73 in U2OS cells,
a human osteosarcoma cell line with wild-type p53. The
enhanced sensitivity to DNA damage was reversed in
a p53/ background, indicating that DNp73 functions
as a negative regulator of p53-dependent apoptosis. The
augmented apoptotic response was accompanied by in-
creased ATM phosphorylation. Wilhelm et al. (2010)
demonstrated that endogenous DNp73b binds 53BP1,
and furthermore found that, upon DNp73 depletion,
localization of 53BP1 to foci of double-stranded breaks
is enhanced. The ability of DNp73 to compromise p53-
dependent apoptosis in MEFs had been demonstrated
earlier (Petrenko et al. 2003). However, the relationship
between DNp73 and 53BP1 is intriguing and suggests
a deeper involvement of DNp73 in the DDR than pre-
viously appreciated. Furthermore, since DNp73 transcrip-
tion is activated via p53 and TAp73 (Kartasheva et al.
2002; Nakagawa et al. 2003), a reasonable conclusion
from the findings of the Mak group (Wilhelm et al. 2010)
is that there is a negative feedback loop between p73 and
p53: Activated p53 initiates transcription of DNp73;
DNp73 binds 53BP1, thereby reducing levels of phosphor-
ylated ATM and stabilizing MDM2, and, ultimately,
inactivating p53.
By overexpressing DNp73, Pozniak et al. (2000) were
able to rescue neuronal cells from p53-induced apoptosis.
This implies that DNp73 exerts its neuroprotective role
via its ability to inhibit p53-dependent apoptosis. How-
ever, Pozniak et al. (2000) also showed that, in cultured
cells, DNp73b can interact directly with p53, and there-
fore they attributed the rescued phenotype to this in-
teraction. In the current study,Wilhelm et al. (2010) show
an interaction between DNp73b and 53BP1. Since it has
been shown that p53 can interact directly with 53BP1
(Iwabuchi et al. 1994; Derbyshire et al. 2002), the
relationship between these three partners—including
ATM and MDM2—might not be as straightforward as
DNp73b/ 53BP1/ATM/MDM2/ p53, but rather,
these players might function as dynamic complexes in
which the stoichiometry dictates the various outcomes of
the DDR. It would be interesting to determine whether
TAp73, as well as TAp63 and DNp63 isoforms, also inter-
acts with 53BP1, since they share the 53BP1-interacting
region found in p53 andDNp73, aswell as to assesswhether
mutation of this region—for example, as found in patients
with split-hand–foot malformation (SHFM) caused by p63
mutations—precludes its interaction with 53BP1.
Senescence as a tumor-suppressive mechanism
When Wilhelm et al. (2010) transformed DNp73/MEFs
by expressing E1A and RASV12, they noted a significant
Figure 1. Model for the role of DNp73b in the DDR. The data
presented by Wilhelm et al. (2010) support a model in which
DNp73b inhibits ATM–p53 signaling. (Left) In normal cells,
DNp73b interacts with 53BP1, and p53 activity is kept in check
via MDM2-mediated degradation. (Right) In response to dsDNA
breaks triggered by DNA damage, the DNp73b:53BP1 complex
is recruited to sites of DNA damage, ATM is activated, and
MDM2’s inhibitory effect on p53 is alleviated; in the absence of
DNp73, this pathway is enhanced. Although p73 is localized to
DNA damage-induced foci under physiological conditions, this
association is clearly not needed for 53BP1 localization, as 53BP1
localizes to sites of DNA damage even in the absence of DNp73.
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delay in tumor initiation, as well as a decrease in tumor
size compared with wild-type controls. Surprisingly, the
reduced capacity of DNp73/ MEFs to form tumors was
not attributed to a higher level of apoptosis, but instead to
enhanced cellular senescence, as demonstrated by in-
creased expression of the senescence markers p16Ink4a,
senescence-associated b-galactosidase (SA-b-gal), and
DcR2. Cellular senescence provides a potent tumor-
suppressive mechanism in vivo (Collado and Serrano
2006). Senescent cells are observed in premalignant
lesions in humans, and escape from this tumor-protective
barrier (in response to activation of oncogenes or in-
activation of tumor suppressors) is a prerequisite for
malignancy.
Previous studies have also implicated p53 family mem-
bers in cellular senescence. Senescent cells express robust
levels of p53, and p53 deficiency compromises senes-
cence, leading to cellular transformation and tumorigen-
esis. It was also shown that deficiency of p63 induces
a program of cellular senescence, and that conditional
ablation of p63 in proliferative cells of the epidermis leads
to accelerated aging in vivo (Keyes et al. 2005). As cellular
senescence protects from malignancy, perhaps this ex-
plains the observation that mice with haploid levels of
p63 are not prone to spontaneous or chemically induced
carcinogenesis (Keyes et al. 2006). It has been shown
recently which p63 isoforms mediate the senescence
response. By engineering a TAp63 conditional mouse
model, Guo et al. (2009) discovered that TAp63 isoforms
are both necessary and sufficient for inducing senescence
in MEFs. Yet, in a distinct cellular context, TAp63 is
essential for primary oocyte death in response to DNA
damage (Suh et al. 2006). DeYoung et al. (2006) brought
p73 into the picture, as they found that depletion of
DNp63 in primary keratinocytes induced cellular senes-
cence in a TAp73-dependent manner, yet in squamous
cell carcinoma cells, depletion of DNp63 induced apopto-
sis independently of TAp73. These results suggested that
p53-related proteins affect distinct pathways modulating
both cellular senescence and apoptosis, consistent with
the findings of Wilhelm et al. (2010) in different settings.
In light of these earlier studies, it would be interesting to
determine whether loss of DNp73 affects the balance
between apoptosis and senescence in an in vivo setting.
The p53 gene is lost in the majority of human cancers,
yet the p63 and p73 loci are typically intact. This suggests
that modulation of p63 and/or p73 activities may be
promising in the clinic. Inducible expression of TAp63
induces p21-mediated cellular senescence that causes
abrupt tumor regression in vivo (Guo et al. 2009). Impor-
tantly, TAp63-mediated cellular senescence in this set-
ting is completely independent of p53. The study by
Wilhelm et al. (2010) suggests that DNp73bworks against
ATM–p53-mediated tumor suppression. It would be in-
teresting to determine whether depletion of DNp73 using
an inducible RNAi strategy could inhibit progression of
tumors that were already established, as well as to assess
whether depletion of DNp73 could inhibit the growth of
tumors lacking p53, as was demonstrated for TAp63 (Guo
et al. 2009).
TAp73/ and TAp73+/mice are tumor-prone, and the
wild-type allele is typically lost in the heterozygotes
(Tomasini et al. 2008). This and other findings have
established TAp73 as a tumor suppressor. In contrast,
a predisposition to spontaneous tumors has not been
reported for DNp73/ mice (Tissir et al. 2009; Wilhelm
et al. 2010). Rather, DNp73 seems to function as an
oncogene. Several observations support this claim.
DNp73 is overexpressed in human cancers (Buhlmann
and Putzer 2008). In lung cancer and neuroblastoma,
DNp73 is correlated with poor prognosis (Casciano et al.
2002; Uramoto et al. 2004), and recurrence of cervical
cancer is more frequent in DNp73-positive patients (Liu
et al. 2006). By targeting DNp73 to the liver, Tannapfel
et al. (2008) developed a model for hepatic cell carcinoma.
In contrast, DNp73 ablation was found to inhibit pro-
liferation of cancer cells in vivo (Emmrich et al. 2009).
The current study by Wilhelm et al. (2010) further
strengthens an oncogenic role for DNp73. Additionally,
they provide a mechanistic basis for this potential with
the finding that DNp73 acts as a negative regulator of p53-
mediated apoptosis via the DNA damage checkpoint
protein 53BP1.
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